Follicular thyroid carcinoma (FTC) represents a smaller but clinically distinct subset of differentiated thyroid cancers. While many patients experience excellent outcomes following surgical management, FTC exhibits a wider range of biologic behavior than papillary thyroid cancer, with a greater propensity for vascular invasion and distant metastasis that directly influence postoperative management decisions. For decades, radioactive iodine (RAI) has played a central role in postoperative management, particularly for patients with high-risk disease.1-3
Current National Comprehensive Cancer Network (NCCN) guidelines advocate for a selective, risk-adapted approach to RAI use.2 High-risk FTC patients are generally recommended to receive adjuvant RAI due to demonstrated survival benefit, while routine use in low-risk patients is discouraged. Despite these guidelines, national practice patterns continue to diverge from guideline treatment recommendations in clinically meaningful ways.
Across large datasets, a consistent pattern emerges. A substantial proportion of high-risk patients do not receive RAI despite evidence of benefit, while many low-risk patients receive RAI without measurable improvement in survival. These deviations raise important questions for surgeons, who often determine the trajectory of postoperative decision-making, multidisciplinary coordination, and referral pathways.
This article examines national cancer database trends in RAI use for FTC and reframes them through a surgeon-facing lens. The goal is to highlight persistent misalignment between risk stratification and adjuvant therapy, explore its implications for patient outcomes and healthcare equity, and outline actionable considerations for surgeons seeking to deliver guideline-concordant, high-value care.
Why Risk-Aligned RAI Use Matters in FTC
Risk stratification is foundational to contemporary thyroid cancer management and central to postoperative planning. In FTC, features such as extrathyroidal extension, vascular invasion, nodal burden, distant metastases, and poor differentiation meaningfully influence recurrence risk and survival. NCCN guidelines incorporate these factors to guide postoperative treatment decisions, including the use of RAI.2
In high-risk FTC, adjuvant RAI has been associated with improved survival, particularly among patients with advanced local disease or metastatic involvement. Conversely, in low-risk FTC, randomized trials and long-term follow-up studies demonstrate that omission of RAI does not compromise oncologic outcomes.4-7
Risk-aligned care matters for several reasons. For high-risk patients, failure to deliver indicated adjuvant therapy represents missed opportunity for survival benefit. For low-risk patients, unnecessary RAI exposes individuals to avoidable risks, including salivary gland dysfunction, secondary malignancy, and financial toxicity, while consuming healthcare resources without clear benefit.
For surgeons, risk alignment is an operational principle rather than an abstract guideline concept. It directly influences postoperative counseling, referral timing, and multidisciplinary planning. Surgical decisions often set the trajectory for downstream care.
National Patterns Reveal Persistent Misalignment
National cancer registry analyses spanning nearly 2 decades reveal a consistent and concerning pattern. Among patients meeting NCCN criteria for high-risk FTC, approximately one-third do not receive adjuvant RAI. At the same time, more than one-third of patients classified as low risk undergo RAI despite lack of demonstrated survival benefit.
These trends persist even after accounting for tumor stage, margin status, and extent of surgery, suggesting that disease severity alone does not explain observed variation. In other words, deviations from guideline-based care cannot be explained solely by disease severity or operative factors.
Several practical and system-level drivers likely contribute to these deviations:
- Therapeutic inertia rooted in historical practice patterns when RAI was more routinely administered
- Overreliance on surgical extent, where total thyroidectomy prompts reflexive RAI use regardless of risk profile
- Uncertainty regarding FTC biology, particularly in cases with borderline or incompletely characterized features
- Fragmentation of postoperative care, with delayed or inconsistent endocrine oncology follow-up
For surgeons, these findings highlight that operative excellence alone does not ensure optimal oncologic care. Alignment with postoperative management pathways is equally critical as misalignment often arises despite appropriate surgical intent. Surgeons may correctly identify risk features at the time of operation, yet downstream care diverges as patients transition between services, institutions, or providers. Without clear ownership of postoperative planning, evidence-based intent can erode across handoffs, leading to both undertreatment and overtreatment.
Where Misalignment Occurs Along the Care Pathway
Misalignment between risk stratification and RAI use emerges cumulatively across the care continuum. Understanding where these inflection points occur allows surgeons to intervene more effectively. Preoperative evaluation represents the first opportunity for alignment. In some cases, incomplete preoperative characterization of FTC risk factors, such as vascular invasion or extent of capsular involvement, limits early anticipation of adjuvant needs. While definitive risk stratification depends on final pathology, early recognition of potential high-risk features can prompt timely planning and referral.
Operative decision-making also plays a role. The extent of surgery may unintentionally signal downstream expectations regarding adjuvant therapy. Total thyroidectomy, while appropriate in many FTC cases, can create an implicit assumption that RAI will follow, even when final pathology demonstrates low-risk disease.
Conversely, conservative surgical approaches in high-risk patients may delay referral for adjuvant evaluation. Pathology reporting represents another critical juncture. Ambiguity in reporting vascular invasion, margin status, or degree of differentiation can complicate risk stratification and lead to inconsistent recommendations. Clear, standardized pathology communication supports appropriate postoperative decisions.
Finally, postoperative referral and follow-up often determine whether guideline-aligned therapy is ultimately delivered. Delays in endocrine oncology consultation, geographic barriers, or fragmented care transitions disproportionately affect high-risk patients and contribute to observed underuse of RAI. Surgeons remain uniquely positioned to coordinate these transitions.
Survival Implications Are Risk-Dependent
The survival associated with RAI in FTC is not uniform. In high-risk patients, receipt of RAI is associated with a meaningful reduction in mortality, reinforcing guideline recommendations. In contrast, no survival benefit is observed among low-risk patients receiving RAI.8-10
This distinction underscores the importance of precision in adjuvant decision-making. When RAI is delivered to patients unlikely to benefit, it dilutes its value while obscuring gaps in care for those who stand to gain the most.
From a surgical perspective, these findings reinforce the need for explicit risk-based conversations during operative planning and early postoperative follow-up. Clear documentation of risk features, margin status, and nodal burden facilitates appropriate downstream decisions.
